Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study

The Lancet

Volumn 374, Issue 9693, 2009, Pages 912-920

  Straathof, Karin C ^a   Rao, Kanchan ^a   Eyrich, Matthias ^b   Hale, Geoff ^c   Bird, Prudence ^c   Berrie, Eleanor ^c   Brown, Lucinda ^a   Adams, Stuart ^a   Schlegel, Paul G ^b   Goulden, Nicholas ^a   Gaspar, H Bobby ^a   Gennery, Andrew R ^d   Landais, Paul ^e   Davies, EG ^a   Brenner, Malcolm K ^f   Veys, Paul A ^a   Amrolia, Persis Jal ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; ITRACONAZOLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITAZOXANIDE; PENICILLIN V; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; CANDIDEMIA; CHEST INFECTION; CHILD; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CRYPTOSPORIDIUM; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; INFANT; LOW DRUG DOSE; MAINTENANCE THERAPY; ORGAN DONOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RETINITIS; RETRANSPLANTATION; SCHOOL CHILD; SIDE EFFECT; SPLEEN DISEASE; STEM CELL TRANSPLANTATION; STOMATITIS; VIREMIA;

EID: 69949094169     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60945-4     Document Type: Article

References (30)

1. Antoine C., Muller S., Cant A., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361 (2003) 553-560
2. Rocha V., Devergie A., Socie G., et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 103 (1998) 243-248
3. van der Burg M., van Veelen L.R., Verkaik N.S., et al. A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation. J Clin Invest 116 (2006) 137-145
4. Buck D., Moshous D., de Chasseval R., et al. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol 36 (2006) 224-235
5. Amrolia P., Gaspar H.B., Hassan A., et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 96 (2000) 1239-1246
6. Jacobsohn D.A., Duerst R., Tse W., and Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 364 (2004) 156-162
7. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105 (2005) 879-885
8. Brazzola P., Duval M., Fournet J.C., et al. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen. Bone Marrow Transplant 36 (2005) 1103-1105
9. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101 (2003) 1620-1629
10. Burroughs L.M., Storb R., Leisenring W.M., et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant 40 (2007) 633-642
11. Dahlke M.H., Lauth O.S., Jager M.D., et al. In vivo depletion of hematopoietic stem cells in the rat by an anti- CD45 (RT7) antibody. Blood 99 (2002) 3566-3572
12. Wulf G.G., Luo K.L., Goodell M.A., and Brenner M.K. Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood 101 (2003) 2434-2439
13. Krance R.A., Kuehnle I., Rill D.R., et al. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant 9 (2003) 273-281
14. O'Driscoll M., Cerosaletti K.M., Girard P.M., et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 8 (2001) 1175-1185
15. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
16. Douek D.C., McFarland R.D., Keiser P.H., et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 396 (1998) 690-695
17. Pannetier C., Cochet M., Darche S., et al. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 90 (1993) 4319-4323
18. Comans-Bitter W.M., de Groot R., van den Beemd R., et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 130 (1997) 388-393
19. Satwani P., Morris E., Bradley M.B., et al. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 50 (2008) 1-8
20. Veys P., Rao K., and Amrolia P. Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning. Bone Marrow Transplant 35 suppl 1 (2005) 45-47
21. Small T.N., Papadopoulos E.B., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell- depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 93 (1999) 467-480
22. Eyrich M., Leiler C., Lang P., et al. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors. Bone Marrow Transplant 32 (2003) 379-390
23. Heitger A., Greinix H., Mannhalter C., et al. Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation. Transplantation 69 (2000) 2366-2373
24. Khouri I.F., McLaughlin P., Saliba R.M., et al. 8-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide and rituximab. Blood 111 (2008) 5530-5536
25. Grigg A.P., Gibson J., Bardy P.G., et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant 13 (2007) 560-567
26. Bindon C.I., Hale G., Clark M., and Waldmann H. Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen: synergy and interference in complement mediated lysis. Transplantation 40 (1985) 538-544
27. Tighe H., Clark M., and Waldmann H. Blocking of cytotoxic T cell function by monoclonal antibodies against the CD45 antigen (T200/leukocyte-common antigen). Transplantation 44 (1987) 818-823
28. Matthews D.C., Appelbaum F.R., Eary J.F., et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94 (1999) 1237-1247
29. Pagel J.M., Appelbaum F.R., Eary J.F., et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107 (2006) 2184-2191
30. Rigaud S., Fondaneche M.C., Lambert N., et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444 (2006) 110-114